Twinbeech Capital LP Biogen Inc. Transaction History

Twinbeech Capital LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$212.02 - $267.71 $21.7 Million - $27.4 Million	102,251 New	102,251 $22 Million
Q3 2023 Nov 14, 2023	BUY	$253.3 - $285.89 $206,692 - $233,286	816 New	816 $209,000
Q1 2023 May 15, 2023	SELL	$256.56 - $292.34 $395,358 - $450,495	-1,541 Reduced 7.39%	19,311 $5.37 Million
Q4 2022 Feb 14, 2023	BUY	$252.44 - $306.72 $5.26 Million - $6.4 Million	20,852 New	20,852 $5.77 Million
Q2 2022 Aug 15, 2022	SELL	$187.54 - $223.02 $118,900 - $141,394	-634 Reduced 5.61%	10,663 $2.18 Million
Q1 2022 May 16, 2022	BUY	$193.77 - $244.14 $1.84 Million - $2.32 Million	9,516 Added 534.31%	11,297 $2.38 Million
Q4 2021 Feb 14, 2022	BUY	$223.92 - $287.77 $398,801 - $512,518	1,781 New	1,781 $427,000
Q3 2020 Nov 16, 2020	SELL	$264.77 - $305.71 $1.06 Million - $1.23 Million	-4,009 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$258.66 - $342.55 $1.04 Million - $1.37 Million	4,009 New	4,009 $1.07 Million

1,018

128M

1.22M

1.4M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $25B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of Twinbeech Capital LP, based on Form 13F filings with the SEC.

Stay updated on Twinbeech Capital LP with notifications on news.